“I‘m certainly not bitter, but maybe a bit disappointed”
He has had a hand in the creation of a number of Danish biotech companies and he has seen both ups and downs. In this interview, Jørgen Drejer talks about why he feels the current venture model is not working.
BY BENJAMIN WERNER CHRISTENSEN
In the first two installments of the miniseries ‘When the ships left the port’, MedWatch has tracked the performances of the Danish biotech companies founded between 2000 and 2004, and examined how experiences made in those years have affected and continue to affect the way venture funds operate to this day.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”Investors are much more cynical today”
For abonnenter
Has Danish biotech been a success?
For abonnenter
